Welcome to our dedicated page for Cullinan Oncology news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Oncology stock.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a clinical-stage biopharmaceutical company developing potential first- or best-in-class therapies for autoimmune diseases and cancer. The CGEM news feed highlights the company’s ongoing clinical progress, regulatory interactions, and scientific presentations across its portfolio of T cell engagers and targeted therapies.
News updates frequently cover clinical trial data for key assets such as CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, and CLN-978, a CD19xCD3 bispecific T cell engager being studied in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease. Releases detail efficacy signals, safety profiles, B cell depletion data, and outcomes in high-risk patient subsets, often presented at major medical meetings like ASH, ASCO, ESMO, ACR, and WCLC.
The CGEM news section also features updates on zipalertinib (CLN-081/TAS6417), an EGFR tyrosine kinase inhibitor for non-small cell lung cancer with EGFR exon 20 insertion and other uncommon mutations, developed in collaboration with Taiho Oncology and Taiho Pharmaceutical. These stories include information on Breakthrough Therapy Designation, rolling New Drug Application submissions, and data from REZILIENT trials, including cohorts with active brain metastases.
Investors and followers of Cullinan Therapeutics can use this page to review corporate updates, SEC-related announcements furnished via press release, and portfolio decisions such as program prioritizations or discontinuations. For anyone tracking CGEM, the news feed provides a consolidated view of the company’s disclosed milestones, scientific progress, and regulatory steps across its autoimmune and oncology programs.
Cullinan Therapeutics (Nasdaq: CGEM) announced management will present at two upcoming investor conferences in early March 2026. CEO Nadim Ahmed and CMO Jeffrey Jones will appear in fireside chats at the TD Cowen 46th Annual Healthcare Conference on March 3 and the Leerink Global Healthcare Conference on March 10. Webcasts will be available under the Events and Presentations section of the company's investor relations website.
Cullinan Therapeutics (Nasdaq: CGEM) will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026 at 10:00 a.m. ET. Speakers include CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A.
A live webcast will be available under the Events and Presentations section of the company’s investor relations website: https://investors.cullinantherapeutics.com/events.
Cullinan Therapeutics (Nasdaq: CGEM) announced that CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A., will take part in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 a.m. ET.
A live webcast will be available via the company’s investor relations Events and Presentations page at https://investors.cullinantherapeutics.com/events.
Cullinan Therapeutics (Nasdaq: CGEM) provided a 2026 corporate update highlighting clinical and regulatory catalysts and its financial position. Key clinical milestones include planned 2026 data readouts for CLN-978 across RA, SLE and Sjögren’s (single-dose and repeat dosing), initiation of monotherapy expansion and a frontline combination study for CLN-049 with an expected RP2D decision in Q4 2026, and a rolling NDA completion for zipalertinib expected in Q1 2026 with REZILIENT3 enrollment completion in H1 2026. Cullinan reported preliminary cash, cash equivalents and investments of $439.0 million as of Dec 31, 2025, and expects runway into 2029.
Cullinan Therapeutics (Nasdaq: CGEM) reported updated Phase 1 results for CLN-049, an investigational FLT3xCD3 T cell engager, presented orally at the 67th ASH meeting on December 8, 2025. In 45 patients (39 AML) across doses 1.5–12 µg/kg, clinically active doses (≥6 µg/kg) showed a CR/CRh 25% (8/32) and CRc 28% (9/32); at 12 µg/kg CR/CRh was 31% (5/16). Among responders at ≥6 µg/kg, 63% had duration >16 weeks; MRD negativity observed in 3/10 patients with marrow blasts <5%. Safety was manageable: CRS in 35.6% (mostly Grade 1–2), febrile neutropenia 20%. CLN-049 received FDA Fast Track and dose escalation and expansion cohorts are planned in early 2026.
Cullinan Therapeutics (Nasdaq: CGEM) announced that the U.S. FDA granted Fast Track designation to CLN-049, a FLT3xCD3 T cell engager, for treatment of relapsed/refractory acute myeloid leukemia (R/R AML) on December 1, 2025. The company said Phase 1 data in heavily pre-treated patients showed promising efficacy and favorable safety, including complete responses. CLN-049 Phase 1 results will be presented in an oral presentation at the 67th ASH Annual Meeting on December 8, 2025. Cullinan stated the Fast Track designation is intended to accelerate development and facilitate collaboration with the FDA to advance CLN-049 for patients with limited treatment options.
Cullinan Therapeutics (Nasdaq: CGEM) and partners Taiho Oncology and Taiho Pharmaceutical announced a rolling submission of a New Drug Application to the U.S. FDA for zipalertinib to seek accelerated approval for treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion (ex20ins) mutations in patients previously treated with platinum chemotherapy.
The companies said zipalertinib previously received Breakthrough Therapy Designation in 2021. The NDA is based on primary efficacy data from the Phase 1/2 REZILIENT1 trial, with positive results presented at ASCO 2025 and published in the Journal of Clinical Oncology. The firms anticipate completing the NDA submission in Q1 2026 and will request priority review.
Cullinan Therapeutics (Nasdaq: CGEM) announced management participation in two investor conferences and an analyst/investor event at the 2025 ASH Annual Meeting.
CEO Nadim Ahmed and CMO Jeffrey Jones will appear in fireside chats at the Stifel Healthcare Conference in New York on Nov 11, 2025 at 3:20 p.m. ET and at the Guggenheim Healthcare Innovation Conference in Boston on Nov 12, 2025 at 8:00 a.m. ET. The company will host an in-person analyst and institutional investor event on Dec 8, 2025 at 8:00 p.m. ET in Orlando following the oral presentation of Phase 1 CLN-049 results in AML/MDS (Presentation ID 768).
Investors may register by emailing nsmith@cullinantx.com. Webcasts will be available on the company investor relations Events and Presentations page.
Cullinan Therapeutics (Nasdaq: CGEM) reported third-quarter 2025 results and a corporate update focused on T cell engager programs in immunology and oncology. Key clinical highlights include ~30% CRc for CLN-049 at clinically active doses in relapsed/refractory AML and planned oral data presentation at ASH 2025 (Dec 8, 2025). CLN-978 (CD19xCD3) will share initial SLE and RA safety and B‑cell depletion data in 1H 2026 and received a U.S. composition‑of‑matter patent extending protection to at least 2042. The company discontinued CLN-619 and CLN-617 and said partner Taiho will begin a rolling NDA for zipalertinib by year‑end, with pivotal enrollment completing in 1H 2026. Cash, cash equivalents and investments totaled $475.5M as of Sept 30, 2025, supporting a runway into 2029.
Cullinan Therapeutics (Nasdaq: CGEM) reported Phase 1 CLN-049 data in relapsed/refractory AML and MDS showing anti-leukemic activity and a manageable safety profile as of a June 2025 cutoff.
Key data: across target doses ≥6 μg/kg (n=23 AML) CRc 30% and ORR 57%; at 12 μg/kg (n=13) CRc 31% and ORR 69%. Responses occurred regardless of FLT3 mutational status, including 4 responses in 5 TP53‑mutated AML patients. CRS occurred in 40% (all Grade 1–2); Grade ≥3 febrile neutropenia and WBC decrease were 17.5% each. Dose escalation is ongoing and updated results will be presented at ASH 2025 on December 8.